Özet:

Despite the increase of resistant microorganism-related infections in recent years, ongoing studies for the deve- lopment of new antibiotics have been very limited. This article reviews the pharmacological properties and the clinical use of linezolid and tigecycline which are impor- tant choices for resistant nosocomial infections, in additi- on to ceftaroline, a newer drug that has not yet been in clinical use in our country. Linezolid, is the first drug of oxazolidinone class of antibiotics which inhibits bacterial protein synthesis. It has clinical indication for resistant gram-positive infections, including VRE, MRSA and resis- tant pnemococci, both in children and adults. Tigecycline binds bacterial ribosomal 30 S subunit like minocycline. It has a broad activity spectrum including resistant gram- positive, gram-negative and anaerobic bacteria other than Pseudomonas aeruginosa. It has clinical use for resistant complicated skin soft tissue and intra-abdominal infections for adults. Ceftaroline, is the newest member of 5th generation cephalosporins. It has antimicrobial acti- vity against resistant gram-positive microorganisms inc- luding methicilline- and vancomycine- resistant Staphylococcus aureus

Anahtar Kelimeler: